This is a working overview of thymosin alpha 1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-01 and is reviewed periodically as new material appears.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
multiple cloning site (MCS) Also polylinker. A locus or sequence within a plasmid vector which contains multiple unique restriction sites recognized by various restriction endonucleases, which makes it possible for scientists to target the insertion of a DNA fragment (often a gene cassette) specifically to that locus and in the desired orientation, by digesting the insert and the vector with the same endonuclease(s) and then ligating them together via compatible restriction ends, a technique known as restriction cloning. Commercial plasmids designed for cloning commonly incorporate one or more multiple cloning sites.
Romania is a unitary semi-presidential representative democratic republic with a structured system of governance and an active civil society. The President, elected by popular vote, serves as the head of state, representing the country in international affairs, safeguarding constitutional order, and acting as supreme commander of the Romanian Armed Forces. The Prime Minister, appointed by the President and confirmed by the Parliament, acts as the head of government, responsible for overseeing the executive branch, implementing domestic and foreign policies, and managing public administration. Legislative authority is vested in a bicameral Parliament, consisting of the Chamber of Deputies and the Senate, whose members are elected through a proportional representation system. The judiciary operates independently, with the High Court of Cassation and Justice as the highest court of appeal. According to International IDEA's Global State of Democracy (GSoD) Indices and Democracy Tracker, Romania performs in the mid- range on overall democratic measures, with particular strengths in inclusive suffrage and elected government.
Huntington's disease has autosomal dominant inheritance, meaning that an affected individual typically inherits one copy of the gene with an expanded trinucleotide repeat (the mutant allele) from an affected parent. Since the penetrance of the mutation is very high, those who have a mutated copy of the gene will have the disease. In this type of inheritance pattern, each offspring of an affected individual has a 50% risk of inheriting the mutant allele and developing the disease (see figure). This probability is sex-independent since the huntingtin gene is not located on the X or Y chromosomes. Trinucleotide CAG repeats numbering over 28 are unstable during replication, and this instability increases with the number of repeats present. This usually leads to new expansions as generations pass (dynamic mutations) instead of reproducing an exact copy of the trinucleotide repeat. This causes the number of repeats to change in successive generations, such that an unaffected parent with an "intermediate" number of repeats (28–35), or "reduced penetrance" (36–40), may pass on a copy of the gene with an increase in the number of repeats that produces fully penetrant HD. The earlier age of onset and greater severity of disease in successive generations due to increases in the number of repeats is known as genetic anticipation. Instability is greater in spermatogenesis than oogenesis; maternally inherited alleles are usually of a similar repeat length, whereas paternally inherited ones have a higher chance of increasing in length.
====== Alcohol-related programmes ====== A high amount of media coverage exists informing people of the dangers of driving drunk. Most people who recreationally consume alcohol are now aware of these dangers and safe ride techniques like 'designated drivers' and free taxicab programmes are reducing the number of drunk-driving crashes. Many cities have free-ride-home programmes during holidays involving high amounts of alcohol use, and some bars and clubs will provide a visibly drunk patron with a free cab ride. In New South Wales groups of licensees have formed local liquor accords and collectively developed, implemented and promoted a range of harm minimisation programmes including the aforementioned 'designated driver' and 'late night patron transport' schemes. Many of the transport schemes are free of charge to patrons, to encourage them to avoid drink-driving and at the same time reduce the impact of noisy patrons loitering around late night venues. Moderation Management is a programme which helps drinkers to cut back on their consumption of alcohol by encouraging safe drinking behaviour. Harm reduction in alcohol dependency could be instituted by use of naltrexone.
== Morphology == These organisms specifically reside in the family Stichodactylidae or the “carpet anemones”. Defined by their distinct morphology, S. helianthus are large anemones that are sessile and range in diameter of 10–20 cm. Their color varies in shades of golden brown, yellow and green. They possess a multitude of nematocyst-coated tentacles that cover their flattened oral disc. The nematocysts play a large role in predation and defense by excreting toxins.
Sources: en.wikipedia.org
The Min System is a mechanism composed of three proteins MinC, MinD, and MinE used by E. coli as a means of properly localizing the septum prior to cell division. Each component participates in generating a dynamic oscillation of FtsZ protein inhibition between the two bacterial poles to precisely specify the mid-zone of the cell, allowing the cell to accurately divide in two. This system is known to function in conjunction with a second negative regulatory system, the nucleoid occlusion system (NO), to ensure proper spatial and temporal regulation of chromosomal segregation and division.
Cambridge University Press. ISBN 978-1-009-04573-5. Morano-Faodi, Sonia & Jen Neller. Fairhurst's law of the European Union, 13th edn. Harlow/NY: Pearson Education, 2020. O'Neill, Aidan (2011). EU Law for UK Lawyers (2nd ed.). Bloomsbury Publishing. ISBN 9781847318107. Reich, Norbert, Annette Nordhausen-Scholes, & Jeremy Scholes. Understanding EU internal market law, 3rd rev'd edn. Cambridge: Intersentia, 2015. Riesenhuber, Karl, ed. European legal methodology, 2nd edn. Cambridge: Intersentia, 2021. Schütze, Robert (2025). European Union Law (4th ed.). Oxford: Oxford University Press. ISBN 9780198941057. Tobler, Christa; Beglinger, Jacques (2020). Essential EU Law in Charts. Budapest HVG-ORAC. ISBN 978-963-258-489-8. Weiler, JHH (1991). "The Transformation of Europe". Yale Law Journal. 100 (8): 2403–2483. doi:10.2307/796898. ISSN 0044-0094. JSTOR 796898.
In January 2023, US president Joe Biden invited Lula to meet him in Washington, D.C., in February 2023 following a phone conversation between them on the 2023 Brazilian Congress attack. White House press secretary Karine Jean-Pierre confirmed the meeting adding that it would address "U.S. support of Brazil's democracy and how the two countries can continue to work together to promote inclusion and democratic values in the region and around the world". Climate change, migration, economic development and security matters were also discussed. In February 2023, Lula and a delegation including his Foreign Affairs special advisor Celso Amorim, Foreign minister Mauro Vieira, Finance minister Fernando Haddad, Racial Equality minister Anielle Franco, Environment e Climate Justice minister Marina Silva travelled to the US. During the trip Lula met with US Senator Bernie Sanders, Democratic House Representatives Alexandria Ocasio-Cortez, Pramila Jayapal, Sheila Jackson Lee, Brad Sherman and Ro Khanna before he met with US president Joe Biden at the White House. On 10 February, at a meeting with American president Joe Biden, Lula proposed the creation of a group of negotiators made up of countries "not involved in the war" (either directly or indirectly, i.e.
== External links == Clinical trial number NCT02666664 for "Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)" at ClinicalTrials.gov Clinical trial number NCT02988115 for "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant (CLEAR Serenity)" at ClinicalTrials.gov Clinical trial number NCT02991118 for "Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk (CLEAR Wisdom)" at ClinicalTrials.gov
Sources: en.wikipedia.org
== Cited sources == Charatan, Fred (2006). "Gulf war symptoms do not constitute a syndrome". BMJ. 333 (7569): 618. doi:10.1136/bmj.333.7569.618-b. JSTOR 40700302. PMC 1570822. PMID 16990302. Greenberg, Neil; Iversen, Amy C.; Unwin, Catherin; Hull, L.; Wessely, S. (2004). "Screening for depleted uranium in the United Kingdom armed forces: who wants it and why?". Journal of Epidemiology and Community Health. 58 (7): 558–561. doi:10.1136/jech.2003.014142. PMC 1732813. PMID 15194715. Moszynski, Peter (2003). "Royal Society warns of risks from depleted uranium". BMJ. 326 (7396): 952. doi:10.1136/bmj.326.7396.952. JSTOR 25454350. PMC 1125878. PMID 12727744. Mould, Richard F. (2001). "Radiation dose from depleted uranium can now be measured". BMJ. 322 (7290): 865–866. doi:10.1136/bmj.322.7290.865/a. JSTOR 25466697. PMC 1120031. PMID 11321019. S2CID 683662. Royal Society working group on the health hazards of depleted uranium munitions (2002). The health hazards of depleted uranium munitions: Part II (Report). London, England: The Royal Society.
=== US FDA approved === The US Food and Drug Administration (FDA) approves anti-obesity medications as an adjunctive therapy to diet and exercise for people for whom lifestyle changes do not result in sufficient weight loss. In the United States, semaglutide (Wegovy) is approved by the FDA for chronic weight management. The FDA guidelines say that a therapy may be approved if it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that comes predominantly from fat mass. Some other prescription weight loss medications are stimulants, which are recommended only for short-term use, and thus are of limited usefulness for patients who may need to reduce weight over months or years. As of 2022, there is no pathway for approval for drugs that reduce fat mass without 5 percent overall weight loss, even if they significantly improve metabolic health; neither is there one for drugs that help patients maintain weight loss although this can be more challenging than losing weight. As of 2022, no medication has been discovered that would equal the effectiveness of bariatric surgery for long-term weight loss and improved health outcomes.
The final step in gluconeogenesis, the formation of glucose, occurs in the lumen of the endoplasmic reticulum, where glucose-6-phosphate is hydrolyzed by glucose-6-phosphatase to produce glucose and release an inorganic phosphate. Like two steps prior, this step is not a simple reversal of glycolysis, in which hexokinase catalyzes the conversion of glucose and ATP into G6P and ADP. Glucose is shuttled into the cytoplasm by glucose transporters located in the endoplasmic reticulum's membrane.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.